These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 27432383

  • 1. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
    Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S.
    Adv Ther; 2016 Sep; 33(9):1519-35. PubMed ID: 27432383
    [Abstract] [Full Text] [Related]

  • 2. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M.
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, Fujinaga A, Kawamoto T, Utsumi T, Yanagawa N, Ichiishi E, Otake T, Kohgo Y, Nomura Y, Ueno N, Sugano H, Kashima S, Moriichi K, Fujiya M, Okumura T.
    Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H.
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [Abstract] [Full Text] [Related]

  • 8. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance.
    Ashida K, Honda Y, Sanada K, Takemura Y, Sakamoto S.
    Expert Opin Drug Saf; 2019 Dec; 18(12):1255-1261. PubMed ID: 31646920
    [Abstract] [Full Text] [Related]

  • 9. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K.
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K.
    Digestion; 2018 Oct; 97(3):212-218. PubMed ID: 29393194
    [Abstract] [Full Text] [Related]

  • 14. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori.
    Kamiya K, Nishio E, Horio A, Tokura Y.
    J Dermatol; 2016 Mar; 43(3):340-1. PubMed ID: 26508502
    [No Abstract] [Full Text] [Related]

  • 15. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL.
    Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
    [Abstract] [Full Text] [Related]

  • 16. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance.
    Graham DY, Lu H, Shiotani A.
    J Gastroenterol Hepatol; 2021 May; 36(5):1159-1163. PubMed ID: 32918832
    [Abstract] [Full Text] [Related]

  • 17. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS.
    World J Gastroenterol; 2015 Jan 07; 21(1):351-9. PubMed ID: 25574111
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S, Nishikawa J, Sakaida I.
    Intern Med; 2020 Jan 15; 59(2):153-161. PubMed ID: 31243237
    [Abstract] [Full Text] [Related]

  • 20. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection.
    Liu L, Nahata MC.
    Ann Pharmacother; 2023 Oct 15; 57(10):1185-1197. PubMed ID: 36688309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.